Display Settings:

Format

Send to:

Choose Destination
    Curr Opin Pharmacol. 2007 Apr;7(2):140-5. Epub 2007 Feb 15.

    Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?

    Source

    Department of Nutrition, Case Western Reserve University, School of Medicine, Cleveland, OH 44106-4906, USA. pre@po.cwru.edu

    Abstract

    Accumulating basic and clinical data support the hypothesis that angiotensin receptor blockers have beneficial effects on glucose and lipid metabolism that are not shared by other classes of antihypertensive agents. These metabolic actions might only partially be shared by angiotensin-converting enzyme inhibitors. Specific benefits beyond those of other angiotensin receptor blockers have been claimed for telemesartan and, to a lesser extent, irbesartan based on a partial agonist action on PPAR-gamma receptors. Although the evidence is strong in vitro, specific actions not shared by other angiotensin receptor blockers have not yet been convincingly demonstrated in vivo or in clinical trials. In many cases, a full range of doses has not been compared, and the apparent superiority of telmesartan could be an artifact of its higher receptor binding affinity, greater tissue penetration owing to lipophilicity, and longer half life.

    PMID:
    17303473
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2930911
    Free PMC Article

    Images from this publication.See all images (1) Free text

    Figure 1

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk